MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
Phase: PHASE2
Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Sponsor: National Cancer Institute (NCI)

i 
28 State Street, Suite 1100, Boston, MA 02109
p: 857.504.2900 
f: 617. 589.0914
ecog-acrin.org
August 19, 2020
Martha Kruhm, MS RAC
Head, Protocol and Information Office
Quality Assurance Section
CTEP, DCT, NCI 
6130 Executive Blvd, EPN Room 7000
Bethesda, MD   20892
Dear Ms. Kruhm:
Enclosed is Addendum #25 to EAY131-C1, Crizotinib in Patients with Tumors with MET 
Amplification
This addendum is in response to Dr. Tali Johnson’s Amendment Request for updates to specific 
protocol language for Crizotinib dated June 5, 2020.
Please replace your current copy of the protocol and Informed Consent document with these 
updated versions. We recommend that each institution maintain a file containing the original 
protocol, Informed Consent, and all subsequent revisions/versions.
IRB Review Requirements:
This addendum has been reviewed and approved by the Central IRB, which is the sole 
IRB of record for this study. Local IRB review and approval is unnecessary.
Implementation of this addendum must occur on the activation date. Sites are not 
permitted to conduct the study utilizing outdated versions of any MATCH protocol documents 
after the activation date of this addendum.
Re: Review of Amendment #36 of Protocol #EAY131-C1: “MATCH Treatment Subprotocol C1: 
Crizotinib in Patients with Tumors with MET Amplification”. The following are ECOG-ACRIN’s 
responses to the CTEP review comments dated 5/26/2020. Please note that the Principal 
Investigator’s comments appear in bold below.
I.
Comments Requiring a Response– Administrative & Editorial Issues:
# 
Section
Comments
1.
ICD- Why is this 
study being 
done?
Under Why is this study being done? on page 1, please change the 
target accrual back to 50, consistent with protocol amendment #35:
There will be about 35 50 people taking part in this study.
PI Response: This has been corrected. 
II.
Additional Protocol Changes by Principal Investigator:
The following revisions to EAY131-C1 protocol have been made in this addendum:

ii 
 
Section 
Change 
1. 
Cover Page 
Updated Version Date and addendum number. 
2. 
Cover Page  
In second note, removed language in second sentence referencing 
an activation memo. 
3. 
3.2.1 
Revised language in the second box referencing “subject’ to 
“female patient” 
4. 
Appendix III 
Updated patient drug information template format. 
The following revisions to EAY131-C1 Informed Consent Document have been made in this 
addendum: 
 
Section 
Change 
1. 
Page 1 
Updated Version Date. 
If you have any questions regarding this addendum, please contact aagu@ecog-acrin.org or 
857-504-2900. 
We request review and approval of this addendum to EAY131-C1 so ECOG-ACRIN may 
activate it promptly.   
Thank you.  
Sincerely, 
Pamela Cogliano 
Senior Director of Protocol Development 
 
 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
2 
Table of Contents
Molecular Analysis for Therapy Choice (MATCH) ...................................................... i
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET 
Amplification....................................................................................................... 1
Table of Contents ...................................................................................................... 2
Schema ...................................................................................................................... 4
1.
Introduction........................................................................................................ 5
1.1
Crizotinib................................................................................................... 5
1.2
Supporting Preliminary Data..................................................................... 7
1.3
MET Amplification Criteria........................................................................ 9
1.4
Arm Expansion .......................................................................................... 9
2.
Selection of Patients .........................................................................................10
2.1
Registration to Treatment.......................................................................10
3.
Crizotinib Treatment Plan.................................................................................12
3.1
Administration Schedule.........................................................................12
3.2
Adverse Event Reporting Requirements.................................................12
3.3
Comprehensive Adverse Events and Potential Risks list (CAEPR) for 
Crizotinib (PF-02341066, NSC 749005)...................................................15
3.4
Dose Modifications .................................................................................19
3.5
Supportive Care.......................................................................................22
3.6
Duration of Agent-specific treatment.....................................................24
3.7
Duration of Follow-Up .............................................................................24
4.
Study Parameters..............................................................................................25
4.1
Therapeutic Parameters for Crizotinib Treatment ................................. 25
5.
Drug Formulation and Procurement................................................................. 27
5.1
Crizotinib (NSC #749005) ........................................................................28
6.
Translational Studies.........................................................................................29
7.
References ........................................................................................................29
Appendix I  Patient Pill Calendar .............................................................................32
Appendix II  CYP3A4 Inducers and Inhibitors ..........................................................34
Appendix III  PATIENT CLINICAL TRIAL WALLET CARD.............................................35
Appendix IV  Medications That May Cause QTc Prolongation................................36
Appendix V  Actionable Mutations for Sub-Protocol EAY131-C1............................38
Rev. 3/17

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
3 
TREATMENT SUBPROTOCOL CHAIR 
David S. Hong, MD 
University of Texas M.D. Anderson Cancer Center 
1515 Holcombe Blvd 
Houston TX 77030 
Phone: 713-563-5844 
Fax: 713-563-0566 
Email: dshong@mdanderson.org 
 
TRANSLATIONAL CHAIR 
Daniel Catenacci, MD 
Univeristy of Chicago 
900 E 57th St, Suite 7128 
Chicago, IL 60637 
Phone: 773-702-7596  
Fax: 773-702-9268 
Email: dcatenac@bsd.uchicago.edu 
 
 
 
 
 
 
 
 
 
 
 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
4 
Schema 
 
 
Long-Term Follow-Up
Crizotinib 250 mg PO BID
Until progression or 
unacceptable toxicity
Cycle = 28 days
Accrual Goal: 50
 
 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
5 
1. 
Introduction 
1.1 
Crizotinib  
1.1.1 
Background 
Deregulated signaling by the epithelial cell receptor tyrosine kinase 
(RTK), MET, appears critical to the growth, invasion, and metastasis 
of many solid tumors. Under physiological conditions, MET and its 
ligand, hepatocyte growth factor (HGF), regulate pathways essential 
for embryogenesis, liver regeneration and wound healing. HGF 
initiates these pathways by inducing MET dimerization and 
autophosphorylation which activates signaling cascades that promote 
cell proliferation, migration, matrix invasion and branching 
morphogenesis (Birchmeier et al., 2003; Comoglio et al., 2008; Naran 
et al., 2009) HGF can also drive aberrant MET signaling in cancer 
through autocrine loops(Catenacci et al., 2011); however, MET 
activation also occurs independently of HGF via gene amplification 
and consequent MET over-expression (Smolen et al., 2006) as well 
as, more rarely, mutation and/or cross-talk with RTKs and other 
receptors. 
Over-expression of MET has been observed in most solid tumors and 
correlates with poor prognosis (Birchmeier et al., 2003; Comoglio et 
al., 2008; Graziano et al., 2011; Naran et al., 2009). MET over-
expression via gene amplification occurs in glioblastoma (< 5%), 
gastric cancer (4-< 5%), and colorectal cancer (< 3%). MET 
amplification also occurs in lung cancer subjects resistant to EGFR 
inhibitors, where it appears to mediate drug resistance (Engelman et 
al., 2007). Germ-line gain-of-function MET mutations commonly occur 
in hereditary papillary renal cancer, and somatic activating MET 
mutations have been reported in head and neck cancer, sporadic 
papillary renal cancer, non Hodgkin’s lymphoma, and rarely in ovarian 
and lung cancer. (Johnson et al. 2012) 
However, the story of MET in all cancers is not entirely clear. For 
example onartuzumab, an antibody that targets the MET receptor, 
combined with erlotinib, showed improved progression free and 
overall survival in the MET positive (assessed by IHC) lung cancer 
population in a phase II trial, but failed to show a difference in 
progression free or overall survival in a large randomized phase 3 trial 
of onartuzumab in combination to erlotinib compared to erlotinib alone 
in non-small lung cancer (median 2.7 versus 2.6 months, P=0.92). 
Moreover the overall survival trended in favor of erlotinib alone (9.1 
months vs 6.8 on the combination m p=0.07). (Spigel et al, ASCO 
2014). 
Likewise, in the Phase III Multinational, Randomized, Double-Blind, 
Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib 
Versus Erlotinib Alone in Previously Treated Patients With Locally 
Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer 
Scagliotti et al (2015) reported that the study was ended early for 
futility and did not improve overall survival. However, in a preplanned 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
6 
subgroup exploratory analysis, of 211 patients with high MET 
expression by IHC,  the combination of erlotinib and tivantinib had 
improved median overall survival (9.3 vs 5.9 months). 
The reasons for failure of these trials in NSCLC is not fully 
understood, but may be due to differences in how MET amplification 
or overexpression were measured. Others have shown that MET 
maybe a valid target in MET amplified NSCLC. For example, D. Ross 
Camidge showed that durable responses were seen in MET high 
amplified NSCLC patients treated with criztoinib (D. Ross Camidge et 
al, ASCO 2014). 
Collectively, however, the data indicate that MET plays a broad and 
supporting role in oncogenesis and drug resistance and that MET is a 
valid target for cancer therapy. 
Crizotinib is an inhibitor of the MET, ALK, and ROS1 receptor tyrosine 
kinases that was recently approved by the Food and Drug 
Administration for treatment of ALK-positive non-small cell lung 
cancer (NSCLC) because of a striking response rate in those tested 
positive for ALK rearrangement. ALK rearrangement can also be 
found in a subset of patients with sarcoma, breast cancer, and 
lymphoma, but their response to this agent is as of yet unknown.  
Recently, Crizotinib also was FDA approved to treat ROS1 positive 
tumors because it was shown to be highly active in the treatment of 
lung cancer harboring ROS1 gene rearrangement (Shaw, et al., 2012 
and its activity as a MET inhibitor in tumors with MET amplification is 
considerable(Tanizaki, et al, 2011; Ou et al., 2011). Despite a proven 
efficacy in these genetic subsets of cancers, acquired or intrinsic 
resistance is common and leads to tumor progression, highlighting the 
need to combine this drug with other agents. 
Crizotinib is an oral small-molecule inhibitor of ALK, MET, and ROS1 
receptor tyrosine kinases.  It was first discovered through a screen of 
inhibitors of MET, the receptor for HGF. The kinase selectivity of 
crizotinib was evaluated against a panel of more than 120 human 
kinases; crizotinib inhibited autophosphorylation of both MET and ALK 
with high potency and specificity (Cui et al, 2011). 
Crizotinib demonstrated concentration-dependent inhibition of ALK 
and MET phosphorylation in cell-based assays using tumor cell lines 
and demonstrated antitumor activity in mice bearing tumor xenografts 
that expressed EML4- or NPM-ALK fusion proteins or MET. 
The IC50 of crizotinib in blocking MET phosphorylation and MET 
dependent cell growth and invasion in a variety of cell lines is 5-20 nM 
(Cui et al, 2011). Crizotinib blocks cell proliferation and enhances 
apoptosis in NSCLC lines carrying an EML4-ALK fusion in the range 
of 250-340 nM. Based upon clinical pharmacokinetic data, more than 
70% of ALK inhibition is projected at the FDA-approved dose of 250 
mg twice a day and, thus, a highly MET inhibition is also expected at 
this dose (Gandhi et al., 2012). 
Administration of crizotinib at pharmacologic doses to MET amplified 
cell lines results in marked inhibition of phosphorylated MET, Akt, Erk, 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
7 
67$7DQG3/&ȜOHYHOV (Zou et al., 2007). A significant dose 
dependent reduction of human VEGFA and IL-8 plasma levels in Met 
positive tumor-bearing mice was also observed. In addition, crizotinib 
potently inhibits HGF-stimulated endothelial cell survival and invasion 
(Cui et al, 2011). These results suggest that antitumor activity of 
crizotinib may be mediated by direct effects upon pivotal pathways in 
cancer cells as well as an antiangiogenic effect. Its activity as a MET 
inhibitor in tumors with MET amplification is considerable(Tanizaki, et 
al, 2011; Ou et al., 2011). 
1.2 
Supporting Preliminary Data  
1.2.1 
Crizotinib Preclinical Pharmacology and Efficacy 
In the preclinical setting, crizotinib blocks MET activation across 
multiple tumor types. Data were generated in gastric and breast 
carcinoma cells, prostate, squamous head and neck cancer, 
osteosarcoma, ovarian cancer and  renal cancer (Zou et al., 2007). 
Convincing pre-clinical evidence for induction of apoptosis by 
crizotinib in gastric cancer cells with MET amplification has been 
published (Sampson et al, 2011). Crizotinib also showed in the lab to 
induce cell death in head and neck cancer when combined with 
dasatinib in cells that were previously resistant to this drug (Sen et al, 
2011). 
1.2.2 
Summary of Clinical Experience 
Crizotinib is approved for use in patients with advanced NSCLC who 
have evidence of anaplastic lymphoma kinase (ALK)-positive tumor 
as detected by the FDA approved test for the EML4-ALK gene fusion. 
This alteration is observed in about 5% of patients with NSCLC. The 
response rates seen in early-phase studies in ALK-positive NSCLC 
led to the accelerated FDA approval of crizotinib in this setting (Kwak 
et al., 2010). In addition to ALK inhibition in NSCLC, there is clinical 
evidence of efficacy of crizotinib in NSCLC harboring ROS1 
rearrangements and in inflammatory myofibroblastic tumor (IMT) and 
anaplastic large-cell lymphoma (ALCL) with ALK aberrations. 
Moreover, crizotinib has shown clinical efficacy in MET amplified 
NSCLC, esophagogastric adenocarcinoma and glioblastoma. 
In a patient with advanced NSCLC whose tumor was identified as 
harboring de-novo MET amplification but no ALK rearrangement by 
FISH (Ou et al., 2011), treatment with crizotinib resulted in rapid tumor 
shrinkage and partial response. This validated MET amplification as a 
molecular driver that could be therapeutically targeted with MET 
inhibitors. Lennerz et al. reported 2 cases of MET-amplified 
esophagogastric cancers which exhibited tumor shrinkage in 
response to crizotinib, again supporting a role for MET inhibitor 
therapy in MET-amplified tumors (Lennerz et al, 2011). Furthermore, 
a case report of a patient with a -MET amplified glioblastoma 
described a rapid clinical improvement and a 40% reduction in the 
central lesion while receiving crizotinib (Chi et al, 2011). Progression 
was detected after 6 months of crizotinib initiation. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
8 
Pharmacokinetics 
Absorption  
The Phase I trial of crizotinib showed that patients treated at the 
recommended phase 2 dose (RP2D) were noted to achieve a Cmax 
of the drug at a median Tmax of 4 hours with a terminal half-life of 42 
hours following a single oral dose. Steady-state levels were reached 
within 15 days, with a non-linear pharmacokinetics as reflected by 
decreases in CL/F observed with multiple doses. Steady state 
systemic exposure (Cmin and AUC) appeared to increase in a greater 
than dose proportional manner over the dose range of 200-300 mg 
twice daily.  
The mean absolute bioavailability of crizotinib was 43% (range: 32% 
to 66%) following the administration of a single 250 mg oral dose. A 
high-fat meal reduced crizotinib AUC and Cmax by approximately 
14%. A mouse model showed that the EC50 for ALK inhibition 
approximately corresponded to the EC50 for tumor growth inhibition, 
suggesting that >50% of ALK inhibition would be required for tumor 
killing of >50%. Based in a non clinical mouse xenograft model more 
than 70% of ALK inhibition is projected in lung cancer patients taking 
the usual dose of crizotinib, 250 mg twice daily. 
Distribution 
The geometric mean volume of distribution (Vss) of crizotinib was 
1,772 L following intravenous administration of a 50 mg dose, 
indicating extensive distribution into tissues from the plasma. Binding 
of crizotinib to human plasma proteins in vitro is 91% and is 
independent of drug concentration. In vitro studies suggested that 
crizotinib is a substrate for P-glycoprotein (P-gp). The blood-to-plasma 
concentration ratio is approximately 1.  
Metabolism 
In vitro studies demonstrated that crizotinib is predominantly 
metabolized by CYP3A4/5 (package insert). Additional information is 
found in Section 5.1.8. The primary metabolic pathways in humans 
were oxidation of the piperidine ring to crizotinib lactam and O-
dealkylation, with subsequent Phase 2 conjugation of O-dealkylated 
metabolites. In vitro studies in human liver microsomes demonstrated 
that crizotinib is a time-dependent inhibitor of CYP3A.  
Elimination 
Following single doses of crizotinib, the mean apparent plasma 
terminal half-life of crizotinib was 42 hours in patients. Following the 
administration of a single 250 mg radiolabeled crizotinib dose to 
healthy subjects, 63% and 22% of the administered dose was 
recovered in feces and urine, respectively. Unchanged crizotinib 
represented approximately 53% and 2.3% of the administered dose in 
feces and urine, respectively. 
The  mean apparent clearance (CL/F) of crizotinib was lower at 
steady state (60 L/hr) after 250 mg twice daily than that after a single 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
9 
250 mg oral dose (100 L/hr), which was likely due to autoinhibition of 
CYP3A by crizotinib after multiple dosing.
1.3
MET Amplification Criteria
It is known that the degree of increase of MET gene copy number (GCN) 
correlates with prognosis in various tumor types (Cappuzzo et al., 2009; 
Graziano et al., 2011) and also the degree of MET protein over-expression 
(Catenacci et al., 2014). The degree of amplification also correlates with 
response to MET TKIs (Lennerz et al., 2011; Smolen et al., 2006). Therefore, 
eligibility for the crizotinib subprotocol of the NCI-MATCH trial will require a 
minimum elevation of gene copy number of 7 copies/cell as assessed by the 
FHQWUDO2QFRPLQH$VVD\ZKLFKZLOOEHFRSLHVSHUFHOO for those Designated 
Laboratories that correct for tumor content.
1.4
Arm Expansion
1.4.1
In some circumstances, it may necessary to expand a treatment arm if 
an inadequate number of assays from Designated Laboratories can 
be confirmed by the central Oncomine® Assay to ensure 31 evaluable 
patients for the primary endpoint. In those circumstances, the study 
will be expanded to achieve a total of 35 patients, i.e. the number of 
cases to allow for attrition so that at least 31 patients are evaluable for 
the primary endpoint.
1.4.2
After the first 35 patients was enrolled on the trial it was suspended 
per protocol guidelines and assessement of confirmation was 
performed. It was determined that only 4 cases were confirmed by the 
central Oncomine® Assay and, when added to the 13 patients that 
were originally assessed by the Oncomine® Assay,  that indicated 
that only 17 patients could be considered evaluable for the primary 
endpoint. Hence, it was decided that an additional 15 patients should 
be accrued for a total of 50 patients to allow a total of 35 patients as 
per guidelines above. In addition, a cut-RIIRIFRSLHVSHUFHOOZDV
set for Designated Laboratories that correct for tumor content as a 
post-hoc evaluation of concordance across treatment arms with 
amplification requirements revealed that these laboratories were 
overcalling copy number as defined by the Oncomine® Assay (see 
Section 1.3 and 2.1.2). If planned accrual is not completed within 21 
months, the expansion cohort will be closed to further accrual.
Rev. Add24

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
10
Rev. Add13
Rev. Add24
2.
Selection of Patients
Each of the criteria in the checklist that follows must be met, along with the eligibility in 
the main screening study, in order for a patient to be considered eligible for this study. 
Use the checklist to confirm a patient’s eligibility. For each patient, this checklist must be 
photocopied, completed and maintained in the patient’s chart. 
In calculating days of tests and measurements, the day a test or measurement is 
done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 
four weeks later would be considered Day 28. 
ECOG-ACRIN Patient No. ____________________________
Patient’s Initials (L, F, M) _______________________
Physician Signature and Date ___________________
NOTE:
All CTEP Policy does not allow for the issuance of waivers to any protocol 
specified criteria 
(http://ctep.cancer.gov/protocolDevelopment/policies deviations.htm). 
Therefore, all eligibility criteria listed in Section 2 must be met, without 
exception. The registration of individuals who do not meet all criteria listed in 
Section 2 can result in the participant being censored from the analysis of the 
study, and the citation of a major protocol violation during an audit. All 
questions regarding clarification of eligibility criteria must be directed to the 
Group's Executive Officer (EA.Execofficer@jimmy.harvard.edu) or the 
Group's Regulatory Officer (EA.RegOfficer@jimmy.harvard.edu).
NOTE:
Institutions may use the eligibility checklist as source documentation if it has 
been reviewed, signed, and dated prior to registration/randomization by the 
treating physician.
NOTE:
All patients must have signed a relevant treatment consent form
2.1
Registration to Treatment 
2.1.1
Patient must fulfill all eligibility criteria outlined in Section 3.1 of 
MATCH Master protocol (excluding Section 3.1.6) at the time of 
registration to treatment step (Step 1, 3, 5, 7).
2.1.2
Patient must have MET amplification as defined via the MATCH 
Master Protocol and described in Appendix V. Amplified MET will be 
defined as  7 copies/cell as identified by the Oncomine® Assay, or 
the Oncomine® Assay equivalent of 7 or greater as identified by a 
Designated Laboratory assay ZKLFKZLOOEHFRSLHVSHUFHOOIRU
those Designated Laboratories that correct for tumor content. See 
Appendix V for information on the MET mutations and corresponding 
Levels of Evidence. 
2.1.3
Patients must have an electrocardigram (ECG) within 8 weeks prior to 
treatment assignment and must not have clinically important 
abnormalities in rhythm, conduction or morphology of resting ECG, 
including complete left bundle branch block, third degree heart block.
Date of ECG:  _______________
_____
_____
_____

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
11
2.1.4
Patients must not have known hypersensitivity to crizotinib or 
compounds of similar chemical or biologic composition.
Date:  _______________
2.1.5
Patient must not have had any of the following prior therapies: AMG 
337, BMS 777607, Cabozantinib (XL184), Crizotinib (PF02341066), 
EMD1214063, Foretinib (GSK1363089) (XL880), Golvatinib (E7050), 
IncB28060 (INC280), JNJ 8877605, MGCD265, MK2461, 
MSC2156119J, PF 04217903, SGX523, Tivantinib (ARQ197) or any 
other novel MET TKI with any MET inhibitory activity IC50 < 1 uM. 
Prior anti-HGF or anti-MET antibodies are acceptable.
2.1.6
Patients must not have a history of extensive disseminated/bilateral or 
known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung 
disease, including a history of pneumonitis, hypersensitivity 
pneumonitis, interstitial pneumonia, interstitial lung disease, 
obliterative bronchiolitis, and pulmonary fibrosis, but not history of 
prior radiation pneumonitis.
2.1.7
Patients must not have had myocardial infarction, severe/unstable 
angina, coronary/peripheral artery bypass graft, congestive heart 
failure, or cerebrovascular accident including transient ischemic attack 
within 3 months prior to start of study treatment * Clinically significant 
GI abnormalities that may alter absorption (e.g., malabsorption 
syndrome, major resection of stomach or small bowel).
2.1.8
Patients using drugs or foods that are known strong CYP3A4 
inhibitors or inducers will be excluded. Patients must not require 
concurrent use of CYP3A substrates with narrow therapeutic indices.
Please see Appendix II. 
2.1.9
Patients must not have had major surgery or tumor embolization 
within 4 weeks and minor surgery within 2 weeks prior to the initiation 
of the study drug.
Physician Signature
Date
OPTIONAL:
This signature line is provided for use by institutions wishing to 
use the eligibility checklist as source documentation.
_____
_____
_____
_____
_____
_____

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
12
Rev. Add25
3. 
Crizotinib Treatment Plan
3.1 
Administration Schedule
Study Drug: Crizotinib
Crizotinib capsules, 250 mg, will be administered orally twice daily on a 
continuous daily dosing schedule. Crizotinib should be taken approximately 12 
hours apart and without regard to meals. Cycles are defined in 28-day periods to 
facilitate scheduling of visits and assessments.
Patients should be instructed that if they vomit after taking a dose, then they 
must not “make it up” with an extra dose, but instead, resume subsequent doses 
as prescribed. Capsules should not be crushed. Any missed dose may be taken 
up to 6 hours prior to the next schedule dose, otherwise it should be skipped and 
dosing resumed with subsequent doses.
3.2
Adverse Event Reporting Requirements
The Adverse Event Reporting Requirements for all EAY131 subprotocols are 
outlined in the MATCH MASTER protocol. Please refer to those guidelines when 
determining if an event qualifies as a Serious Adverse Event (SAE) and requires 
expedited reporting via CTEP’s Adverse Event Reporting System (CTEP-AERS). 
In addition, the following section outlines agent specific requirements and must 
be followed to ensure all reporting requirements are met.
3.2.1
Additional adverse event reporting instructions, requirements and 
instructions for protocol EAY131 – Subprotocol C1 
Additional Instructions
For instructions on how to specifically report events that result in 
persistent or significant disability/incapacity, congenital anomaly, 
or birth defect events via CTEP-AERS, please contact the AEMD 
Help Desk at aemd@tech-res.com  or 301-897-7497. This will 
need to be discussed on a case-by-case basis.
EAY131-C1 specific expedited reporting requirements:
x
Pregnancies: Pregnancies and suspected pregnancies 
(including a positive or inconclusive pregnancy test, regardless 
of age or disease state) occurring while the female patient is on 
crizotinib, or within 28 days of the female patient’s last dose of 
crizotinib, are considered immediately reportable events. The 
pregnancy, suspected pregnancy, or positive/ inconclusive 
pregnancy test must be reported via CTEP-AERS within 24 
hours of the Investigator’s knowledge. Please refer to Appendix 
VIII in MATCH screening protocol for detailed instructions on 
how to report the occurrence of a pregnancy as well as the 
outcome of all pregnancies.
Rev. 3/17

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
13 
EAY131-C1 specific expedited reporting exceptions: 
For study Subprotocol C1, the adverse events listed below do not 
require expedited reporting via CTEP-AERS: 
x 
If an AE meets the reporting requirements of the protocol, and 
it is listed on the SPEER, it should ONLY be reported via 
CTEP-AERS if the grade being reported exceeds the grade 
listed in the parentheses next to the event.”  
3.2.2 
Second Primary Cancer Reporting Requirements 
All cases of second primary cancers, including acute myeloid 
leukemia (AML) and myelodysplastic syndrome (MDS), that occur 
following treatment on NCI-sponsored trials must be reported to 
ECOG-ACRIN using Medidata Rave 
x 
A second malignancy is a cancer that is UNRELATED to any 
prior anti-cancer treatment (including the treatment on this 
protocol).  Second malignancies require ONLY routine reporting 
as follows: 
1. 
Complete a Second Primary Form in Medidata Rave within 
14 days. 
2. 
Upload a copy of the pathology report to ECOG-ACRIN via 
Medidata Rave confirming the diagnosis. 
3. 
If the patient has been diagnosed with AML/MDS, upload a 
copy of the cytogenetics report (if available) to ECOG-
ACRIN via Medidata Rave. 
x 
A secondary malignancy is a cancer CAUSED BY any prior anti-
cancer treatment (including the treatment on this protocol). 
Secondary malignancies require both routine and expedited 
reporting as follows: 
1. 
Complete a Second Primary Form in Medidata Rave within 
14 days 
2. 
Report the diagnosis via CTEP-AERS at 
http://ctep.cancer.gov  
Report under a.) leukemia secondary to oncology 
chemotherapy, b.) myelodysplastic syndrome, or c.) 
treatment related secondary malignancy 
3. 
Upload a copy of the pathology report to ECOG-ACRIN via 
Medidata Rave and submit a copy to NCI/CTEP confirming 
the diagnosis. 
4. 
If the patient has been diagnosed with AML/MDS, upload a 
copy of the cytogenetics report (if available) to ECOG-
ACRIN via Medidata Rave and submit a copy to NCI/CTEP. 
NOTE: 
The Second Primary Form and the CTEP-AERS report 
should not be used to report recurrence or development of 
metastatic disease. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
14 
NOTE: 
If a patient has been enrolled in more than one NCI-
sponsored study, the Second Primary Form must be 
submitted for the most recent trial. ECOG-ACRIN must be 
provided with a copy of the form and the associated 
pathology report and cytogenetics report (if available) even 
if ECOG-ACRIN was not the patient's most recent trial. 
NOTE: 
Once data regarding survival and remission status are no 
longer required by the protocol, no follow-up data should 
be submitted via CTEP-AERS or by the Second Primary 
Form. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
18 
HEPATOBILIARY DISORDERS - Hepatobiliary disorders - Other (cholestasis); Hepatobiliary 
disorders - Other (hepatitis) 
IMMUNE SYSTEM DISORDERS - Autoimmune disorder 
INFECTIONS AND INFESTATIONS - Abdominal infection; Infections and infestations - Other 
(peridiverticular abscess); Kidney infection; Lung infection; Sepsis; Skin infection; Urinary tract 
infection 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Injury, poisoning and 
procedural complications - Other (traumatic lung injury); Spinal fracture; Wound complication 
INVESTIGATIONS - Blood lactate dehydrogenase increased; CPK increased; GGT increased; 
Investigations - Other (monocyte count increased); Investigations - Other (platelet count 
increased); Platelet count decreased 
METABOLISM AND NUTRITION DISORDERS - Dehydration; Hyperglycemia; Hyperkalemia; 
Hypermagnesemia; Hypertriglyceridemia; Hypoalbuminemia; Hypocalcemia; Hypokalemia; 
Hyponatremia; Hypophosphatemia; Metabolism and nutrition disorders - Other 
(hypoproteinemia) 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; 
Musculoskeletal and connective tissue disorder - Other (myopathy); Myalgia; Pain in extremity 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) - 
Treatment related secondary malignancy; Tumor hemorrhage 
NERVOUS SYSTEM DISORDERS - Intracranial hemorrhage; Ischemia cerebrovascular; 
Pyramidal tract syndrome; Seizure; Stroke 
PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS - Pregnancy loss 
PSYCHIATRIC DISORDERS - Confusion; Delirium; Euphoria 
RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria; Renal calculi; Urinary 
retention 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Bronchopulmonary 
hemorrhage; Dyspnea; Pleural effusion; Respiratory failure; Respiratory, thoracic and 
mediastinal disorders - Other (pneumomediastinum); Respiratory, thoracic and mediastinal 
disorders - Other (respiratory distress) 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Skin and subcutaneous tissue disorders 
- Other (drug eruption) 
VASCULAR DISORDERS - Hematoma; Hypotension; Phlebitis; Thromboembolic event; 
Vasculitis 
NOTE: 
Crizotinib (PF-02341066) in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by the other agent, 
or the combination may result in events never previously associated with either 
agent. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
19 
3.4 
Dose Modifications  
All toxicity grades below are described using the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. 
All appropriate treatment areas should have access to a copy of the CTCAE 
version 4.0. A copy of the CTCAE version 4.0 can be downloaded from the 
CTEP website (http://ctep.cancer.gov). 
Patients will be monitored closely for toxicity and the dose of crizotinib may be 
adjusted as indicated in Table 3.5. Intrapatient dose reduction by 1, and if 
needed, 2 dose level(s) will be allowed depending on the type and severity of 
toxicity encountered. 
Dose Level 
Crizotinib Dose 
1 
250mg BID 
-1 
200mg BID 
-2 
250mg Daily 
Patients requiring more than 2 dose reductions due to treatment-toxicity will be 
removed from treatment. Patients requiring treatment to be held for >4 weeks will 
be taken off treatment.  

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
20 
Table 3.5 
Crizotinib Dose Modifications for Treatment-Related Toxicity 
Toxicity 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Non- hematologic General 
(except as noted below), eg, 
neuropathy, edema (including 
peripheral edema and localized 
edema), fatigue, and skin rash 
(including erythematous, macular, 
papular, and pruritic rash) 
Continue at the same 
dose level. 
Continue at the same 
dose level. 
Withhold dose until toxicity is Grade 
1, or has returned to baseline, then 
resume treatment at the same dose 
level or reduce the dose by 1 level at 
the discretion of the investigator.* 
Withhold dose until toxicity is 
Grade 1, or has returned to 
baseline, then reduce the dose 
by 1 level and resume 
treatment, or discontinue at the 
discretion of the investigator*. 
Grade 3 or 4 alanine 
aminotransferase (ALT) or 
aspartate aminotransferase (AST) 
elevation ZLWK*UDGHWRWDO
bilirubin 
Continue at the same 
dose level. 
Continue at the same 
dose level. Obtain 
repeat ALT and total 
bilirubin when 
symptomatic or within 
7 days. 
:LWKKROGXQWLOUHFRYHU\WR*UDGH
or baseline, then resume at 200 mg 
twice daily. In case of recurrence, 
ZLWKKROGXQWLOUHFRYHU\WR*UDGH
then resume at 250 mg once daily. 
Permanently discontinue in case of 
further Grade 3 or 4 recurrence. 
See Grade 3. 
Grade 2, 3 or 4 ALT or AST 
elevation with concurrent Grade 
2, 3 or 4 total bilirubin elevation 
(in the absence of cholestasis or 
hemolysis) 
Continue at the same 
dose level. Obtain repeat 
ALT and total bilirubin 
within 48 hours. 
Discontinue treatment 
and do not retreat 
Discontinue treatment and do not 
retreat 
Discontinue treatment and do 
not retreat 
Left ventricular systolic 
dysfunction 
Continue at the same 
dose level 
Continue at the same 
dose level 
Discontinue treatment and do not 
retreat 
Discontinue treatment and do 
not retreat 
Prolonged QTc  
Continue at the same 
dose level 
Assess electrolytes 
and concomitant 
medications. Correct 
any electrolyte or 
magnesium 
abnormalities 
:LWKKROGXQWLOUHFRYHU\WR*UDGH
then resume at 200 mg twice daily In 
case of recurrence, withhold until 
UHFRYHU\WR*UDGHWKHQUHVXPH
at 250 mg once daily. Permanently 
discontinue in case of further Grade 
3 or 4 recurrence. 
Discontinue treatment and do 
not retreat 
Pneumonitis (in absence of 
disease progression, pulmonary 
embolism, positive cultures or 
radiation effect) 
Discontinue treatment 
and do not retreat 
Discontinue treatment 
and do not retreat 
Discontinue treatment and do not 
retreat 
Discontinue treatment and do 
not retreat 
Visual disturbance 
Continue at the same 
dose level. Repeat 
ophthalmologic 
examination+ 
Continue at the same 
dose level. Repeat 
ophthalmologic 
examination+ 
Interrupt crizotinib until recovery. 
Repeat ophthalmologic examination+. 
Resume treatment by reducing by 
one dose level. 
Discontinue treatment and do 
not retreat. Repeat 
ophthalmologic examination+. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
21 
Toxicity 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Hematologic (excluding 
lymphopenia**) 
Continue at the same 
dose level. 
Continue at the same 
dose level. 
Withhold dose until toxicity is Grade 
 2, or has returned to baseline, then 
resume treatment at the same dose 
level or reduce by 1 level after 
discussion with the study chair**/***. 
Withhold dose until toxicity is 
*UDGH 2, or has returned to 
baseline, then reduce the dose 
by 1 level and resume 
treatment**. 
Hypophosphatemia or 
hyperuricemia* 
Continue at the same 
dose level 
Continue at the same 
dose level 
Continue at the same dose level at 
investigator discretion 
Discontinue treatment until 
resolution to grade 3 or lower 
* Patients who develop Grade 3 hyperuricemia or Grade 3 hypophosphatemia without clinical symptoms may continue study treatment without 
interruption at the discretion of the investigator. Nausea, vomiting or diarrhea must persist at Grade 3 or 4 despite maximal medical therapy, to 
require dose modification. 
** Patients who develop Grade 3 or 4 lymphopenia without other dose-limiting events (eg, opportunistic infection) may continue study treatment 
without interruption. 
*** Patients entering with platelet counts > 30,000 (to < 50,000/μL) will be monitored for drug related decreases at which point dose modifications will 
be discussed with the Sponsor 
§ Patients entering with ALT and/or AST 5 x ULN (ie, Grade 3) due to underlying malignancy will be monitored for potential drug related 
increases at which point dose modifications will be discussed with the Sponsor (Note: this option does not apply for France). 
+ Ophthalmologic examination includes visual acuity and slit lamp and should be performed by an ophthalmologist. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
22 
3.4.1 
Missed Doses 
A missed dose will not be made up. In the event that a subject 
requires an unscheduled interruption of crizotinib under conditions 
other than those associated with toxicity, the case will be reviewed by 
the Study Chair to determine whether such a subject will be allowed to 
resume crizotinib treatment.  
3.5 
Supportive Care  
Throughout the duration of the study, all herbal supplements, vitamins, and 
nutritional supplements taken must be reviewed and approved by the Investigator 
prior to administration. 
3.5.1 
Nausea and emesis: For nausea and vomiting, treat with standard 
anti-emetics such as prochloroperazine or ondansetron. Patients 
should be counseled that taking the medication with food may reduce 
nausea. The use of prophylactic antiemetics should be considered. 
Given the potential for ondansetron to increase QTc prolongation, 
review baseline QTc EKG prior to initiation of ondansetron and 
consider follow up EKGs on treatment. 
3.5.2 
Diarrhea: For grade 1 diarrhea, symptomatic care such as loperamide 
(Imodium) or no intervention at investigator judgment. For grade 2 
diarrhea, loperamide (4 mg at first onset, then 2 mg every 2-4 hrs until 
symptom free for 12 hours). See Table 3.5.for instructions on dose 
modifications. 
3.5.3 
Bradycardia:   
Toxicity 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Bradycardia 
(heart rate 
less than 60 
beats per 
minute) 
Continue 
at the 
same 
dose 
level. 
:LWKKROGXQWLOUHFRYHU\WR*UDGH
RUWRKHDUWUDWH 60. 
Evaluate concomitant medications 
known to cause bradycardia, as well 
as anti-hypertensive medications. 
If contributing concomitant 
medication is identified and 
discontinued, or its dose is adjusted, 
resume at previous dose upon 
UHFRYHU\WR*UDGHRUWRKHDUW
UDWH 60. 
If no contributing concomitant 
medication is identified, or if 
contributing concomitant medications 
are not discontinued or dose 
modified, resume at reduced dose 
XSRQUHFRYHU\WR*UDGHRUWR
KHDUWUDWH 
Same as for 
Grade 2 
bradycardia. 
Permanently 
discontinue if no 
contributing 
concomitant 
medication is 
identified. 
If contributing 
concomitant 
medication is 
identified and 
discontinued, or its 
dose is adjusted, 
resume at 250 mg 
once daily upon 
recovery to Grade  
 1 or to heart rate  
 60, with frequent 
monitoring. 
Permanently 
discontinue for 
recurrence. 

ECOG-ACRIN
EAY131-C1
Cancer Research Group
Version Date: August 19, 2020
23
3.5.4
Pneumonitis/pneumonia: Investigators must evaluate thoroughly 
patients who demonstrate potential signs or symptoms of pneumonitis 
or pneumonia. If a patient has a potential diagnosis of pneumonitis or 
drug-related lung injury, the following evaluations/procedures should 
be considered to assist or exclude the diagnosis of pneumonitis:
x
Evaluate for pneumonia: Pneumonia would be supported by 
clinical symptoms/signs of infection, including fever, leukocytosis, 
productive cough, characteristic radiologic findings, and most 
importantly, documentation of microbiology studies (sputum 
gram/stain and culture, blood cultures). Pneumonia should be 
treated with the appropriate antibiotics and supportive care. Many 
of these symptoms/signs may be seen in pneumonitis, but in this 
case, all microbiological studies would be negative (including 
possibly bronchoscopy for specimens).
x
Sputum gram stain and culture (induced sputum if needed), to 
evaluate for bacterial, viral, fungal, protozoal, and mycobacterial 
infections
x
Blood cultures if febrile
x
Thoracentesis if pleural fluid is present (examined for the same 
pathogens as in 3.6.4.1)
x
Bronchoscopy with bronchoalveolar lavage (BAL) if appropriate.  
BAL fluid should be sent for culture and cytology
x
Lung biopsy if appropriate and necessary to distinguish between 
pneumonia and pneumonitis
x
BNP levels to evaluate for heart failure
x
If clinically appropriate, particularly if pneumonia can be ruled out, 
high dose corticosteroid treatment should be initiated. Should the 
event be fatal, an autopsy is recommended to confirm/exclude the 
diagnosis. 
3.5.5
Renal cysts:  Complex renal cysts have been reported in some 
patients treated with crizotinib. These cysts may be symptomatic or 
asymptomatic, and typically develop between 2 and 6 months after 
starting crizotinib. The precise nature and significance of these cysts 
is unclear. However, complex renal cysts can be associated with renal 
malignancy, so consultation with a urologist is recommended. 
Urinalysis should be performed if renal cysts are detected, and 
followed on Day 1 of each cycle thereafter. Urine reflex microscopy is 
required if the urinalysis demonstrates blood or protein.
3.5.6
Hypogonadism:  For males reporting symptoms of hypogonadism 
(fatigue, sexual dysfunction, decreased libido, mood or sleep disorder, 
gynecomastia), a panel of blood tests should be drawn, including total 
testosterone, free testosterone, and sex-hormone binding globulin 
(SHBG). If free testosterone is low, consultation with endocrinology is 
recommended for possible testosterone supplementation.
Rev. 12/16

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
24 
3.6 
Duration of Agent-specific treatment  
In the absence of treatment delays due to adverse event(s), treatment may 
continue until one of the following criteria applies: 
x 
Extraordinary Medical Circumstances: If at any time the constraints of this 
protocol are detrimental to the patient's health, protocol treatment should be 
discontinued. In this event submit forms according to the instructions in the 
MATCH Forms Packet. 
x 
Patient withdraws consent. 
x 
Patient experiences unacceptable toxicity. 
x 
Non-protocol therapies are administered. 
x 
Disease progression 
3.7 
Duration of Follow-Up  
Refer to the MATCH Master Protocol for specifics on the duration of follow-up. 
 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
25
4.
Study Parameters
4.1
Therapeutic Parameters for Crizotinib Treatment  
NOTE:
In addition to the study parameters listed in the MATCH Master Protocol, the below parameters must also be 
performed for patients receiving crizotinib treatment. 
NOTE:
$OODVVHVVPHQWVUHTXLUHGSULRUWRUHJLVWUDWLRQWRWUHDWPHQWVKRXOGEHGRQHZHHNVSULRUWRUHJLVWUDWLRQWR
Steps 1, 3, 5, 7, excluding the radiologic evaluation and electrocardiogram (ECG). 
Test/Assessment
Prior to Registration 
to Treatment
Treatment
End of 
Treatment
Follow UpF
Every Cycle, prior to 
treatment
Every 2 Cycles
H&P, Weight, Vital signsA
X 
 XJ 
X 
Performance status
X 
 XJ
X 
CBC w/diff, pltsB
X 
 XJ
X 
Serum chemistryB
X 
 XJ
X 
Radiologic evaluationD 
X 
 XD 
 XF
E-HCGC
X 
Toxicity AssessmentG
X 
X 
 XF
Pill Count/DiaryH
X 
X 
ECGK 
X 
 XI 
Tumor biopsy and blood sample for MATCH 
Master protocolE
X 
X 
A. History and physical, including vital signs and weight at the start of each cycle (up to 3 days before start of new cycle). Particular attention should 
be given to any signs of pulmonary fibrosis (shortness of breath, cough); these symptoms should be pursued with appropriate tests.  Patients 
should be instructed to notify their provider if they have increased shortness of breath or cough.
B. Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, creatinine, glucose, phosphorus, potassium,  SGOT[AST], SGPT[ALT], 
sodium, magnesium and serum tumor markers (including LDH, PSA if appropriate).  For eligibility purposes, participants with creatinine levels 
above institutional normal, Cockcroft-Gault will be used to calculate creatinine clearance.  CBC w/diff, platelets and serum chemistries should be 
performed on cycle 1, day 1 (or up to 7 days prior), and at the start of each subsequent cycle (up to 3 days before start of new cycle).  CBC with 
differential will be performed more frequently in patients with grade 4 neutropenia or thrombocytopenia until resolution to JUDGH CBC and 
serum chemistries are only required in follow-up until values return to pre-treatment levels or until progressive disease.
C. Blood pregnancy test (women of childbearing potential) required prior to beginning treatment.
4
Rev. 12/16
Rev. 3/17
Rev. Add13

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
26 
D. Disease measurements are repeated every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until PD or start of another MATCH 
treatment step. The baseline evaluation should be performed as closely as possible to the beginning of treatment and never more than 6 weeks 
before registration to treatment step. For multiple myeloma patients, please refer to Section 6.4 of the MATCH Master Protocol for additional 
information on myeloma response criteria and the required disease assessments. Documentation (radiologic) must be provided for patients 
removed from study for progressive disease. 
E. Additional blood specimens and/or biopsies are to be submitted from consenting patients per Section 9.3.2 of the MATCH Master Protocol. Submit 
at the following time points, as applicable: 
x 
Blood specimens are to be submitted at the end of Cycle 2 (prior to start of Cycle 3 treatment). If patient progresses or treatment is 
discontinued prior to Cycle 3, collect the blood at that time instead. On-treatment kits for blood sample collections will be automatically shipped 
to sites upon registration to the treatment step. 
x 
Screening biopsies for additional aMOI assessments after registration to appropriate screening step, if applicable (Step 2 or Step 4). 
x 
At end of all MATCH study treatments, blood specimens and/or research biopsy after consent and registration to Step 8 
Please refer to Section 4 of the MATCH Master Protocol to determine whether the patient proceeds to the next screening step or to follow-up (with 
a potential end of treatment biopsy for research purposes on Step 8). Samples are to be submitted as outlined in Section 9 of the MATCH Master 
Protocol. To order Step 2/4 Screening or Step 8 kits, complete the EAY131 Collection and Shipping Kit Order Form (See Appendix XII of the 
MATCH Master Protocol) and fax to 713-563-6506. 
F. Every 3 months if patient is < 2 years from study entry, and every 6 months for year 3. Toxicity assessments and radiologic evaluations are not 
required to be done during Follow Up if progression has been previously reported; however if an adverse event occurs post treatment that meets 
the SAE reporting requirements, it still must be reported via CTEP-AERS, even if progression has occurred. 
G. Site personnel should evaluate for toxicity and discuss treatment compliance with the patient in order to ensure the medication is taken correctly; 
this evaluation may be conducted by telephone or in person. The Toxicity Assessment is not required prior to Cycle 1, but is required every 
subsequent cycle. 
H. The pill calendar will be collected at the end of every cycle. The Pill Count/Diary is not required prior to Cycle 1, but is required every subsequent 
cycle. 
I. As clinically indicated. 
J. For Cycle 1, if the following tests/assessments occurred within 7 days of Day 1, they do not need to be repeated at this timepoint: H&P, Weight, 
Vital Signs; Performance Status; CBC w/diff, plts; Serum chemistry; Concomitant Medications.  
K. Within 8 weeks of treatment assignment. 
 
 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
27
5.
Drug Formulation and Procurement
This information has been prepared by the ECOG-ACRIN Pharmacy and Nursing 
Committees.
Availability
NO STARTER SUPPLIES MAY BE ORDERED. Subjects must be enrolled and 
assigned to the treatment arm prior to submitting the clinical drug request to PMB.
Drug Ordering: NCI supplied agents may be requested by eligible participating 
Investigators (or their authorized designee) at each participating institution.
Pharmaceutical Management Branch (PMB) policy requires that drug be shipped 
directly to the institution where the patient is to be treated. PMB does not permit the 
transfer of agents between institutions (unless prior approval from PMB is obtained – 
see general information) The CTEP-assigned protocol number must be used for 
ordering all CTEP-supplied investigational agents. The eligible participating 
investigators at each participating institution must be registered with CTEP, DCTD 
through an annual submission of FDA Form 1572 (Statement of Investigator), NCI 
Biosketch, Agent Shipment Form, and Financial Disclosure Form (FDF). If there are 
several participating investigators at one institution, CTEP-supplied investigational 
agents for the study should be ordered under the name of one lead investigator at that 
institution.  
Submit agent requests through the PMB Online Agent Order Processing (OAOP) 
application (https://ctepcore.nci.nih.gov/OAOP). Access to OAOP requires the 
establishment of a CTEP Identity and Access Management (IAM) account 
(https://ctepcore.nci.nih.gov/iam/) and the maintenance of an “active” account status,  a 
“current” password, and an active person registration status.” 
NCI Supplied Agent(s) – General Information
Questions about drug orders, transfers, returns, or accountability should be 
addressed to the PMB by calling 240-276-6575 Monday through Friday between 
8:30 AM and 4:30 PM Eastern Time.
Drug Returns: All undispensed drug supplies should be returned to the PMB. When it is 
necessary to return study drug (e.g., sealed bottles remaining when PMB sends a stock 
recovery letter), investigators should return the study drug to the PMB using the NCI 
Return Agent Form available on the NCI home page (http://ctep.cancer.gov).  
Drug Accountability: The investigator, or a responsible party designated by the 
investigator, must maintain a careful record of the receipt, disposition, and return of 
agent received from the PMB using the NCI Investigational Agent Accountability Record 
Form for Oral Agents available on the NCI home page (http://ctep.cancer.gov).  Maintain 
separate NCI Investigational Agent Accountability Records for each agent, strength, 
formulation and ordering investigator.
Investigator Brochure Availability: The current versions of the IBs for PMB-supplied 
agents will be accessible to site investigators and research staff through the PMB Online 
Agent Order Processing (OAOP) application. Access to OAOP requires the 
establishment of a CTEP Identity and Access Management (IAM) account and the 
maintenance of an “active” account status, a “current” password, and active person 
registration status. Questions about IB access may be directed to the PMB IB 
coordinator at IBCoordinator@mail.nih.gov. 
Rev. 12/16
Rev. 3/17
Rev. Add13

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
28 
5.1 
Crizotinib (NSC #749005) 
5.1.1 
Other Names  
Xalkori®, PF-02341066 
5.1.2 
Classification  
MET inhibitor 
5.1.3 
Mode of Action  
Crizotinib is a selective ATP-competitive small –molecule inhibitor of 
anaplastic lymphoma kinase (ALK), MET/hepatocyte growth factor 
receptor (HGFR) and Recepteur d’Origine Nantais (RON), and ROS1 
receptor tyrosine kinases and their oncogenic variants. Translocations 
of these genes can result in expression of oncogenic fusion proteins 
that contribute to increased cell proliferation and survival. Antitumor 
efficacy of crizotinib is correlated to pharmacodynamic inhibition of 
phosphorylation of ALK fusion variants or MET /HGFR in tumors in 
vivo. 
5.1.4 
Storage and Stability  
Storage: Store at room temperature 20° to 25° C (68° to 77° F). 
Stability:  Shelf life is consistent with commercially-labeled product. 
5.1.5 
Dose Specifics  
Crizotinib capsules, 250 mg, will be administered orally twice daily on 
a continuous daily dosing schedule. 
See Section 3.4 for dose modifications. 
5.1.6 
Preparation  
Pfizer supplies and PMB, CTEP, DCTD distributes commercially-
labeled crizotinib as 200 mg (size 1, white opaque body and pink 
opaque cap, with “Pfizer” on the cap and “CRZ 200” on the body) and 
250 mg (size 0, pink opaque body and cap, with “Pfizer” on the cap 
and “CRZ 250 on the body) hard gelatin capsules. Each bottle 
contains 60 capsules. 
Excipients include colloidal silicon dioxide, microcrystalline cellulose, 
anhydrous dibasic calcium phosphate, sodium starch glycolate, 
magnesium stearate, and hard gelatin capsule shells as inactive 
ingredients. 
The pink opaque capsule shell components contain gelatin, titanium 
dioxide, and red iron oxide. The white opaque capsule shell 
components contain gelatin, and titanium dioxide. The printing ink 
contains shellac, propylene glycol, strong ammonia solution, 
potassium hydroxide, and black iron oxide. 
5.1.7 
Route of Administration  
Oral. Take with or without food. 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
29
5.1.8
Potential drug-interactions
Crizotinib is primarily metabolized by CYP 3A4/5 with minor 
contributions from CYP2C8, CYP2C19, and CYP2D6. Avoid 
concomitant use of strong CYP3A inhibitors and inducers. Use of 
potent CYP3A inducers should be avoided for at least 12 days prior to 
the first dose of crizotinib. Use of strong CYP3A inhibitors should be 
avoided for at least 7 days prior to the first dose of crizotinib. Exercise 
caution with concomitant use of moderate CYP3A inhibitors. Crizotinib 
moderately inhibits CYP3A4 in a time-dependent fashion. Use caution 
with patients who receive CYP3A4 substrates with a narrow 
therapeutic index.
Crizotinib is an inhibitor of CYP2B6 in vitro. Use caution with co-
administered drugs that are predominantly metabolized by CYP2B6.
Studies demonstrate that crizotinib is a substrate of P-gp and a weak 
BCRP inhibitor, however the potential to cause drug-drug interactions 
at therapeutic doses is low.  Crizotinib inhibited P-gp, OCT1, and 
OCT2 in vitro at clinically relevant concentrations. Use caution with 
co-administration of P-gp, OCT1, and OCT2 substrates.
5.1.9
Side Effects 
See Section Error! Reference source not found. for side effects.
6.
Translational Studies
Please refer to the MATCH Master Protocol for information on the Translational Studies.
7.
References
1.
Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F. (2003). Met, 
metastasis, motility and more. Nature reviews Molecular cell biology 4, 915-925.
2.
Camidge D.R., Ou S.I., Shapiro G, Otterson G.A., et al. Efficacy and safety of 
crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer 
(NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8001)
3.
Cappuzzo, F., Janne, P.A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., 
Zucali, P.A., Terracciano, L., Toschi, L., Roncalli, M., et al. (2009). MET increased 
gene copy number and primary resistance to gefitinib therapy in non-small-cell 
lung cancer patients. Annals of oncology : official journal of the European Society 
for Medical Oncology / ESMO 20, 298-304.
4.
Catenacci, D.V., Henderson, L., Xiao, S.Y., Patel, P., Yauch, R.L., Hegde, P., Zha, 
J., Pandita, A., Peterson, A., and Salgia, R. (2011). Durable complete response of 
metastatic gastric cancer with anti-Met therapy followed by resistance at 
recurrence. Cancer discovery 1, 573-579.
5.
Catenacci, D.V., Liao, W.L., Thyparambil, S., Henderson, L., Xu, P., Zhao, L., 
Rambo, B., Hart, J., Xiao, S.Y., Bengali, K., et al. (2014). Absolute quantitation of 
Met using mass spectrometry for clinical application: assay precision, stability, and 
correlation with MET gene amplification in FFPE tumor tissue. PloS one 9, 
e100586.
6.
Chi AS, Batchelor TT, Kwak EL, et al. Rapid radiographic and clinical improvement 
after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-
epithelial transition inhibitor. J Clin Oncol 2011;30:e30-3.
Rev.Add13

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
30 
7. 
Comoglio, P.M., Giordano, S., and Trusolino, L. (2008). Drug development of MET 
inhibitors: targeting oncogene addiction and expedience. Nature reviews Drug 
discovery 7, 504-516. 
8. 
Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-
02341066), a potent and selective dual inhibitor of mesenchymal-epithelial 
transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med 
Chem 2011;54:6342-63. 
9. 
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., 
Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., et al. (2007). MET 
amplification leads to gefitinib resistance in lung cancer by activating ERBB3 
signaling. Science 316, 1039-1043. 
10. Gandhi L, Janne PA. Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: 
A New Targeted Therapy for a New Target. Clin Cancer Res 2012. 
11. Graziano, F., Galluccio, N., Lorenzini, P., Ruzzo, A., Canestrari, E., D'Emidio, S., 
Catalano, V., Sisti, V., Ligorio, C., Andreoni, F., et al. (2011). Genetic activation of 
the MET pathway and prognosis of patients with high-risk, radically resected 
gastric cancer. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 29, 4789-4795. 
12. Johnson JL, Pillai S, Chellappan SP (2012). Genetic and Biochemical Alterations in 
Non-Small Cell Lung Cancer. Biochemistry Research International. 
2012;2012:940405. doi:10.1155/2012/940405. 
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in 
non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. 
14. Lennerz, J.K., Kwak, E.L., Ackerman, A., Michael, M., Fox, S.B., Bergethon, K., 
Lauwers, G.Y., Christensen, J.G., Wilner, K.D., Haber, D.A., et al. (2011). MET 
amplification identifies a small and aggressive subgroup of esophagogastric 
adenocarcinoma with evidence of responsiveness to crizotinib. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 29, 4803-
4810. 
15. Naran, S., Zhang, X., and Hughes, S.J. (2009). Inhibition of HGF/MET as therapy 
for malignancy. Expert opinion on therapeutic targets 13, 569-581.  
16. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual 
mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) 
inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J 
Thorac Oncol 2011;6:942-6. 
17. Sampson ER, Martin BA, Morris AE, et al. The orally bioavailable met inhibitor PF-
2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a 
xenograft model. J Bone Miner Res 2011;26:1283-94. 
18. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, 
Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross 
JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III Multinational, 
Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus 
Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally 
Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 
2015 Aug 20;33(24):2667-74. 
19. Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between 
c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck 
cancer. Clin Cancer Res 2011;17:514-24. 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
31 
20. Shaw ATC, D.R.; Engelman, G.A. Clinical activity of crizotinib in advanced non-
small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. In: 2012 
ASCO Annual Meeting. Chicago, IL: Journal of Clinical Oncology 2012:Abstr 7508. 
21. Smolen, G.A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., 
Kim, W.J., Okimoto, R.A., Bell, D.W., Sgroi, D.C., et al. (2006). Amplification of 
MET may identify a subset of cancers with extreme sensitivity to the selective 
tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of 
Sciences of the United States of America 103, 2316-2321. 
22. Spigel DR, Edelman MJ, O'Byrne K et al;.Onartuzumab plus erlotinib versus 
erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal 
phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) 
global trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8000). 
23. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib 
(PF-02341066) shows differential antitumor effects in non-small cell lung cancer 
according to MET alterations. J Thorac Oncol 2011;6:1624-31. 
24. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, 
PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and 
antiangiogenic mechanisms. Cancer Res 2007;67:4408-17. 
 

ECOG-ACRIN
EAY131-C1 
Cancer Research Group
Version Date: August 19, 2020
32
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol C1: Crizotinib/MET Amplification
Appendix I 
Patient Pill Calendar
Storage: Store at Room Temperature
Pill Calendar Directions
1. Take your scheduled dose of each capsule. If you take your capsules twice a day, 
the capsules must be taken 12 hours apart.
2. Any missed dose may be taken up to 6 hours prior to the next scheduled dose, 
otherwise it should be skipped and dosing resumed with subsequent doses.  
3. Please bring the empty bottle or any leftover capsules and your pill calendar to your 
next clinic visit.
4. Swallow capsules whole and do not take if the capsules are broken.
5. Take with or without food. Taking with food may decrease nausea.
6. If you vomit after a study dose, another dose should not be taken; instead, wait and 
resume drug dosing at your next scheduled dose.
Rev. 3/17

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
33 
Patient Pill Calendar 
This is a calendar on which you are to record the time and number of capsules you take each 
day. You should take your scheduled dose of each capsules. Note the times and the number 
of capsules that you take each day. If you develop any side effects, please record them and 
anything you would like to tell the doctor in the space provided. Bring any unused capsules and 
your completed pill calendar to your doctor’s visits. 
Crizotinib 
DAY  
Date 
Time capsules 
taken 
Number of 
capsules taken 
Use the space below to make notes 
about things you would like to tell the 
doctor (including unusual symptoms 
you experience, other medicine you 
have taken and anything else you 
think would be of interest.) 
AM 
PM 
Month 
Day 
Year 
AM 
PM 
1 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
10 
 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
 
12 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
18 
 
 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
20 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
24 
 
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
 
28 
 
 
 
 
 
 
 
 
Patient Signature: __________________________________ Date: _____________ 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
34 
Molecular Analysis for Therapy Choice (MATCH) 
MATCH Treatment Subprotocol C1: Crizotinib/MET Amplification 
Appendix II 
 
CYP3A4 Inducers and Inhibitors 
Because the lists of these agents are constantly changing, it is important to regularly 
consult a frequently-updated list such as Facts and Comparisons or Lexicomp; medical 
reference texts such as the Physicians’ Desk Reference may also provide this 
information. The Principal Investigator should be alerted if the subject is taking any agent 
on these lists. 
 
List of CYP3A4 Inducing Agents: 
Carbamazepine 
Phenytoin 
Dexamethasone 
Primidone 
Ethosuximide 
Progesterone 
Glucocorticoids 
Rifabutin 
Griseofulvin 
Rifampin 
Modafinil 
Rifapentine 
Naficillin 
Rofecoxib 
Nelfinavir 
St. John’s Wort 
Nevirapine 
Sulfadimidine 
Oxcarbazepine 
Sulfinpyrazone 
Phenobarbitol 
Tipranavir 
Phenylbutazone 
Troglitazone 
List of CYP3A4 Inhibitors: 
Amiodarone 
 
Mifepristone 
Cimetidine 
 
Nefazodone 
Ciprofloxacin 
 
Nelfinavir 
Clarithromycin 
 
Norfloxacin 
Delavirdine 
 
Norfluoxetine 
Diethyl-dithiocarbamate 
 
Ritonavir 
Diltiazem 
 
Roxithromycin 
Erythromycin 
 
Saquinavir 
Fluconazole 
 
Troleandomycin 
Fluvoxamine 
 
Voriconazole 
Gestodene 
 
Warfarin 
Grapefruit or Grapefruit juice 
 
Amprenavir 
Indanvir 
 
Atazanavir 
Itraconazole 
 
Miconazole 
Ketoconazole 
 
Telithromycin 
Mibefradil 
 
Verapamil 
 
 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
36 
Molecular Analysis for Therapy Choice (MATCH) 
MATCH Treatment Subprotocol C1: Crizotinib/MET Amplification 
Appendix IV 
 
Medications That May Cause QTc Prolongation 
Drugs that are generally 
accepted to have a risk of 
causing Torsades de 
Pointes 
Drugs that in some reports have 
been associated with Torsades 
de Pointes and/or QTc 
prolongation but at this time lack 
substantial evidence for causing 
Torsades de Pointes 
Drugs that, in some reports, have been weakly 
associated with Torsades de Pointes and/or QTc 
prolongation but that are unlikely to be a risk for 
Torsades de Pointes when used in usual 
recommended dosages and in subjects without 
other risk factors (e.g., concomitant QTc prolonging 
drugs, bradycardia, electrolyte disturbances, 
congenital long QTc syndrome, concomitant drugs 
that inhibit metabolism) 
Generic/Brand Name 
Generic/Brand Name 
Generic/Brand Name 
Amiodarone /Cordarone® 
Alfuzosin /Uroxatral® 
Amitriptyline /Elavil® 
Amiodarone /Pacerone® 
Amantadine /Symmetrel® 
Ciprofloxacin /Cipro® 
Arsenic trioxide 
/Trisenox® 
Atazanavir /Reyataz® 
Citalopram /Celexa® 
Astemizole /Hismanal® 
Azithromycin /Zithromax® 
Clomipramine /Anafranil® 
Bepridil /Vascor® 
Chloral hydrate /Noctec® 
Desipramine /Pertofrane® 
Chloroquine /Aralen® 
Clozapine /Clozaril® 
Diphenhydramine /Benadryl® 
Chlorpromazine 
/Thorazine® 
Dolasetron /Anzemet® 
Diphenhydramine /Nytol® 
Cisapride /Propulsid® 
Dronedarone /Multaq® 
Doxepin /Sinequan® 
Clarithromycin /Biaxin® 
Felbamate /Felbatrol® 
Fluconazole /Diflucan® 
Disopyramide /Norpace® 
Flecainide /Tambocor® 
Fluoxetine /Sarafem® 
Dofetilide /Tikosyn® 
Foscarnet /Foscavir® 
Fluoxetine /Prozac® 
Domperidone /Motilium® 
Fosphenytoin /Cerebyx® 
Galantamine /Reminyl® 
Droperidol /Inapsine® 
Gatifloxacin /Tequin® 
Imipramine /Norfranil® 
Erythromycin /Erythrocin® 
Gemifloxacin /Factive® 
Itraconazole /Sporanox® 
Erythromycin /E.E.S.® 
Granisetron /Kytril® 
Ketoconazole /Nizoral® 
Halofantrine /Halfan® 
Indapamide /Lozol® 
Mexiletine /Mexitil® 
Haloperidol /Haldol® 
Isradipine /Dynacirc® 
Nortriptyline /Pamelor® 
Ibutilide /Corvert® 
Lapatinib /Tykerb® 
Paroxetine /Paxil® 
Levomethadyl /Orlaam® 
Lapatinib /Tyverb® 
Protriptyline /Vivactil® 
Mesoridazine /Serentil® 
Levofloxacin /Levaquin® 
Sertraline /Zoloft® 
Methadone /Dolophine® 
Lithium /Lithobid® 
Solifenacin /VESIcare® 
Methadone /Methadose® 
Lithium /Eskalith® 
Trimethoprim-Sulfa /Sulfa® 
Pentamidine /Pentam® 
Moexipril/HCTZ /Uniretic® 
Trimethoprim-Sulfa /Bactrim® 
Pentamidine /NebuPent® 
Moxifloxacin /Avelox® 
Trimipramine /Surmontil® 
Pimozide /Orap® 
Nicardipine /Cardene® 
  
Probucol /Lorelco® 
Nilotinib /Tasigna® 
  
Procainamide /Pronestyl® 
Octreotide /Sandostatin® 
  

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
37 
Drugs that are generally 
accepted to have a risk of 
causing Torsades de 
Pointes 
Drugs that in some reports have 
been associated with Torsades 
de Pointes and/or QTc 
prolongation but at this time lack 
substantial evidence for causing 
Torsades de Pointes 
Drugs that, in some reports, have been weakly 
associated with Torsades de Pointes and/or QTc 
prolongation but that are unlikely to be a risk for 
Torsades de Pointes when used in usual 
recommended dosages and in subjects without 
other risk factors (e.g., concomitant QTc prolonging 
drugs, bradycardia, electrolyte disturbances, 
congenital long QTc syndrome, concomitant drugs 
that inhibit metabolism) 
Generic/Brand Name 
Generic/Brand Name 
Generic/Brand Name 
Procainamide /Procan® 
Ofloxacin /Floxin® 
  
Quinidine /Cardioquin® 
Ondansetron /Zofran® 
  
Quinidine /Quinaglute® 
Oxytocin /Pitocin® 
  
Sotalol /Betapace® 
Paliperidone /Invega® 
  
Sparfloxacin /Zagam® 
Perflutren lipid microspheres 
/Definity® 
  
Terfenadine /Seldane® 
Quetiapine /Seroquel® 
  
Thioridazine /Mellaril® 
Ranolazine /Ranexa® 
  
  
Risperidone /Risperdal® 
  
  
Roxithromycin* /Rulide® 
  
  
Sertindole /Serlect® 
  
  
Sertindole /Serdolect® 
  
  
Sunitinib /Sutent® 
  
  
Tacrolimus /Prograf® 
  
  
Tamoxifen /Nolvadex® 
  
  
Telithromycin /Ketek® 
  
  
Tizanidine /Zanaflex® 
  
  
Vardenafil /Levitra® 
  
  
Venlafaxine /Effexor® 
  
  
Voriconazole /VFend® 
  
  
Ziprasidone /Geodon® 
  
 

ECOG-ACRIN 
EAY131-C1 
Cancer Research Group 
Version Date: August 19, 2020 
38 
Molecular Analysis for Therapy Choice (MATCH) 
MATCH Treatment Subprotocol C1: Crizotinib/MET Amplification 
Appendix V 
 
Actionable Mutations for Sub-Protocol EAY131-C1 
 
Gene Name 
Variant ID 
Variant Type 
Level of Evidence 
Code 
aMOI 
MET 
MET 
CNV 
2